Table 2.
Pre- and post-intervention outcomes per study group and incremental effect of adherence-contingent rebates at Month 6
| Outcomes | Average change from baseline at Month 6 | Incremental effect of adherence-contingent rebatesa | ||
|---|---|---|---|---|
| Control (%) | Adherence-contingent rebates (%) | Estimate (%) | 95% CI | |
| Primary outcome | ||||
| Adherent days | – 14.9** | – 2.73 | 12.2** | 1.43 to 22.9 |
| Secondary outcomes | ||||
| Proportion of patients with adherence ≥ 75% | – 21.4** | – 13.2* | 8.2 | – 9.8 to 26.2 |
| Proportion of patients with adherence ≥ 90% | – 19.6** | – 7.1 | 12.5 | – 5.3 to 30.2 |
| Intraocular pressure | – 2.88** | – 2.20** | 0.687 | – 0.786 to 2.16 |
| GQL | – 1.40* | – 0.951 | 0.452 | – 1.64 to 2.54 |
| EQ-5D-5L | 0.016 | 0.017 | 0.001 | – 0.075 to 0.077 |
| Mean cost of financial incentives | 8.07 | 5.06 to 11.1 | ||
| Explanatory outcomes | ||||
| Days where all doses were taken irrespective of time | – 13.9** | – 8.19** | 5.67 | – 4.38 to 15.7 |
| Doses taken on time | – 13.0** | – 4.88** | 8.16* | – 1.35 to 17.7 |
| Doses taken irrespective of time | – 11.3** | – 7.50** | 3.80 | – 4.15 to 11.8 |
Source: author calculations using the data collected from the study
CI confidence interval, GQL Glaucoma Quality of Life
*Statistically significant at the 10% level; **statistically significant at the 5% level
aCalculated as the difference in change from baseline at Month 6 between that adherence-contingent rebates and control groups